Repatha vs Praluent Side Effects: Head-to-Head Safety Comparison

Why Compare Side Effects Between Two PCSK9 Inhibitors?

Both evolocumab and alirocumab are fully human monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), and both reduce LDL-C by 50 to 60% on top of maximally tolerated statin therapy. No direct randomized head-to-head safety trial exists between them. The comparison must be synthesized from FOURIER (N=27,564, median follow-up 2.2 years) and ODYSSEY OUTCOMES (N=18,924, median follow-up 2.8 years), the two largest PCSK9 inhibitor cardiovascular outcomes trials [1][2].

Both trials enrolled patients with established atherosclerotic cardiovascular disease (ASCVD) and reported similar 15% relative reductions in major adverse cardiovascular events (MACE). Their safety databases are large enough to detect uncommon adverse events at frequencies above 0.5%. Because these trials used statin-treated populations, background rates of myalgia and transaminase elevation were already elevated, making the incremental safety signal from PCSK9 inhibition easier to isolate.

The 2022 European Atherosclerosis Society (EAS) consensus statement on PCSK9 inhibitor safety concluded that both agents demonstrate "a favorable safety profile consistent across trials and post-marketing surveillance" [3]. The American College of Cardiology (ACC) 2022 expert consensus pathway does not differentiate between the two on safety grounds [4].

Injection-Site Reactions

Injection-site reactions (ISRs) represent the most commonly cited local adverse event for both drugs, though rates remain low. In FOURIER, ISRs occurred in 2.1% of the evolocumab group versus 1.6% with placebo [1]. In the phase III OSLER-1 extension study (N=1,324 to 5 years), the cumulative ISR rate for evolocumab reached 3.2% [5].

Alirocumab ISR rates in ODYSSEY OUTCOMES were 3.8% versus 2.1% for placebo [2]. A pooled analysis of 14 ODYSSEY phase III trials (N=3,340 alirocumab-treated patients) reported ISRs in 7.2% of patients on alirocumab versus 5.1% on placebo, with the majority graded as mild and transient [6].

The slightly higher ISR signal with alirocumab in pooled phase III data may reflect differences in injection volume (1 mL for alirocumab 150 mg vs 1 mL for evolocumab 140 mg) and citrate-containing formulations in early alirocumab prefilled syringes. Sanofi reformulated the alirocumab pen to a citrate-free version in 2019. Since reformulation, post-marketing ISR reports have declined. Neither drug produces the lipoatrophy or panniculitis seen with older injectable biologics.

Neurocognitive Effects

When the FDA approved both agents in 2015, it required post-marketing neurocognitive studies because very low LDL-C levels (<25 mg/dL) raised theoretical concerns about CNS cholesterol homeostasis. The EBBINGHAUS trial (N=1,974), a prespecified FOURIER substudy, directly assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB) over a median of 19 months [7]. Results showed no difference in spatial working memory, executive function, or processing speed between evolocumab and placebo, even among patients who achieved LDL-C <25 mg/dL.

ODYSSEY OUTCOMES included a prespecified neurocognitive adverse event analysis. Self-reported neurocognitive events occurred in 1.2% of the alirocumab group versus 1.2% of placebo [2]. A 2020 post-hoc analysis of ODYSSEY OUTCOMES patients who achieved LDL-C <15 mg/dL (N=839) found no excess neurocognitive signal compared with patients who maintained LDL-C between 25 and 50 mg/dL [8].

The 2023 Endocrine Society Clinical Practice Guideline on lipid management states: "Available evidence does not support a causal relationship between very low LDL-C achieved with PCSK9 inhibitors and neurocognitive impairment" [9]. Clinicians can reassure patients that neither drug impairs memory or cognition.

Musculoskeletal Complaints

Myalgia is common in statin-treated populations (5 to 10% prevalence). A frequent reason patients are referred for PCSK9 inhibitor therapy is statin intolerance driven by muscle symptoms. Both evolocumab and alirocumab have been studied in statin-intolerant cohorts.

In the GAUSS-3 trial (N=511), evolocumab produced myalgia in 21% of patients previously intolerant to at least two statins, versus 29% with ezetimibe [10]. In ODYSSEY ALTERNATIVE (N=361), alirocumab produced skeletal muscle events in 32.5% versus 41.1% with atorvastatin rechallenge, with a treatment discontinuation rate of 15.9% versus 22.2% [11].

In the large outcomes trials with patients already tolerating statins, neither PCSK9 inhibitor increased musculoskeletal adverse events above placebo rates. FOURIER reported myalgia in 4.0% evolocumab versus 3.8% placebo [1]. ODYSSEY OUTCOMES reported musculoskeletal pain in 5.6% versus 5.3% [2]. These numbers confirm that PCSK9 inhibition itself does not produce muscle toxicity.

Hepatic Safety

Statin therapy can raise alanine aminotransferase (ALT), so liver safety is always monitored when adding lipid-lowering agents. In FOURIER, ALT greater than 3 times the upper limit of normal (ULN) occurred in 1.0% of evolocumab patients versus 1.0% of placebo [1]. In ODYSSEY OUTCOMES, ALT greater than 3× ULN occurred in 1.7% versus 1.6% [2].

A 2021 systematic review of 38 randomized trials involving 60,684 patients treated with PCSK9 inhibitors found no statistically significant increase in hepatic enzyme elevations (pooled OR 1.01 to 95% CI 0.89, 1.14) [12]. Neither drug carries a hepatotoxicity warning in its prescribing information.

Immunogenicity and Anti-Drug Antibodies

Both agents are fully human IgG monoclonal antibodies, which reduces immunogenicity compared with chimeric or humanized constructs. In the evolocumab program, binding anti-drug antibodies (ADAs) were detected in 0.3% of patients, with no neutralizing antibodies identified [5]. In the alirocumab program, binding ADAs occurred in 5.1% of patients in pooled phase III data, but neutralizing antibodies were rare (0.5%) and transient, with no effect on LDL-C lowering efficacy or safety profile [6].

The higher binding ADA rate with alirocumab does not appear clinically meaningful. No cases of ADA-related hypersensitivity, reduced efficacy over time, or immune-complex disease have been attributed to either agent in post-marketing surveillance through 2025.

Diabetes Risk

Statins modestly increase new-onset diabetes risk. Whether PCSK9 inhibitors compound this effect has been studied prospectively. In FOURIER, new-onset diabetes occurred in 8.1% of evolocumab patients versus 7.7% of placebo (HR 1.05 to 95% CI 0.94, 1.17, not significant) over 2.2 years [1]. In ODYSSEY OUTCOMES, new-onset diabetes was 9.6% alirocumab versus 10.1% placebo, with a non-significant trend toward lower diabetes incidence in the alirocumab group [2].

A 2022 Mendelian randomization study of PCSK9 loss-of-function variants suggested a modest theoretical increase in diabetes risk with lifelong PCSK9 reduction, but clinical trial durations of 2 to 3 years have not demonstrated this signal [13]. Neither drug's label includes a diabetes warning.

Serious Adverse Events and Discontinuation Rates

Overall serious adverse event (SAE) rates were balanced between treatment and placebo in both trials. FOURIER reported SAEs in 24.8% evolocumab versus 24.7% placebo [1]. ODYSSEY OUTCOMES reported SAEs in 20.2% alirocumab versus 20.8% placebo [2].

Treatment discontinuation due to adverse events was low for both: 1.6% for evolocumab in FOURIER and 2.1% for alirocumab in ODYSSEY OUTCOMES [1][2]. These discontinuation rates compare favorably with oral lipid-lowering agents.

Dr. Robert Giugliano, lead author of FOURIER and professor at Harvard Medical School, stated in a 2023 review: "After nearly a decade of clinical experience and over 3 million patient-years of exposure, the safety database for PCSK9 inhibitors as a class is remarkably reassuring, with no unexpected safety signals emerging in post-marketing surveillance" [14].

Dosing Flexibility and Its Safety Implications

Evolocumab is available as 140 mg every 2 weeks or 420 mg once monthly. The monthly dose uses three 140 mg injections via the Pushtronex on-body infusor or three sequential autoinjector administrations. No dose titration is required. This fixed-dose approach means patients cannot reduce their dose if they experience mild adverse effects while maintaining partial efficacy.

Alirocumab offers dose titration: 75 mg every 2 weeks as the starting dose, with uptitration to 150 mg every 2 weeks if LDL-C response is insufficient. This tiered approach allows clinicians to maintain patients on the lower 75 mg dose if it achieves target LDL-C, potentially reducing injection-site discomfort and overall drug exposure. In ODYSSEY OUTCOMES, 53% of patients remained on the 75 mg dose throughout the trial [2].

The 2022 ACC expert consensus pathway notes that alirocumab's dose titration "may offer a practical advantage in patients who experience dose-related local tolerability issues" [4].

Special Populations: Renal and Hepatic Impairment

Neither evolocumab nor alirocumab is renally cleared (both are catabolized by the reticuloendothelial system), so no dose adjustment is needed for chronic kidney disease. In a subgroup analysis of FOURIER patients with eGFR <60 mL/min/1.73m² (N=2,740), evolocumab's safety profile was consistent with the overall population [15].

For hepatic impairment, evolocumab has been studied in patients with mild impairment (Child-Pugh A), showing no meaningful pharmacokinetic differences. Alirocumab pharmacokinetics were similarly unaffected by mild hepatic impairment. Neither agent has been studied in moderate-to-severe hepatic impairment (Child-Pugh B or C), and both labels advise caution in this population.

Post-Marketing Safety Surveillance

The FDA Adverse Event Reporting System (FAERS) database through Q4 2025 shows injection-site reactions as the most commonly reported event for both drugs. Neither agent has received a black box warning, new safety communication, or Risk Evaluation and Mitigation Strategy (REMS) since approval [16].

The European Medicines Agency (EMA) 2024 periodic safety update reports for both evolocumab and alirocumab confirmed that no new safety signals have emerged in over 8 years of post-marketing experience. Rare reports of allergic reactions (urticaria, rash) exist for both, occurring in fewer than 1 in 1,000 treated patients.

Dr. Jennifer Robinson, professor of epidemiology at the University of Iowa and ODYSSEY OUTCOMES steering committee member, wrote in a 2024 commentary: "The choice between evolocumab and alirocumab should be driven by patient preference for device and dosing schedule, formulary access, and cost. Safety differences between the two agents are clinically negligible" [17].

Practical Selection: When Safety Might Tip the Balance

For most patients, the side-effect profiles of Repatha and Praluent are interchangeable. Three narrow clinical scenarios might favor one over the other on tolerability grounds:

First, patients with ISR sensitivity who prefer less frequent injections may favor evolocumab 420 mg monthly (one Pushtronex session per month vs. two alirocumab injections). Second, patients who want the lowest possible biologic exposure while meeting LDL-C targets may prefer alirocumab 75 mg Q2W, which delivers 37.5 mg per week versus evolocumab's minimum of 70 mg per week. Third, patients with a strong preference for pen-style devices over autoinjectors may find one device more comfortable than the other, affecting adherence and thereby real-world safety outcomes.

Adherence itself is a safety issue. A 2023 real-world analysis of 14,892 PCSK9 inhibitor users in a US claims database found 12-month persistence rates of 58% for evolocumab versus 54% for alirocumab, with ISRs cited as the primary tolerability reason for discontinuation in both groups [18].